Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22
Open Access
- 1 January 1999
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 6 (1) , 12-21
- https://doi.org/10.1038/sj.gt.3300838
Abstract
We demonstrate that fusion proteins consisting of the herpes simplex virus (HSV) transport protein VP22 linked in frame to HSV thymidine kinase (tk) retain the ability to be transported between cells. In vivo radiolabelling experiments and in vitro assays show that the fusion proteins also retain tk activity. When transfected COS cells, acting as a source of the VP22-tk chimera, were co-plated on to gap junction-negative neuroblastoma cells, ganciclovir treatment induced efficient cell death in the recipient neuroblastoma cell monolayer. No such effect was observed with COS cells transfected with tk alone. Tumours established in mice with neuroblastoma cell lines expressing VP22-tk regressed upon administration of ganciclovir. Furthermore tumours established from 50:50 mixtures of VP22-tk transduced and nontransduced cells also regressed while no significant effect was observed in similar experiments with cells transduced with tk alone. VP22 mediated transport may thus have application in a clinical setting to amplify delivery of the target protein in enzyme-prodrug protocols.Keywords
This publication has 17 references indexed in Scilit:
- Intercellular delivery of functional p53 by the herpesvirus protein VP22Nature Biotechnology, 1998
- In vitro and in vivo antitumor effects of retrovirus-mediated herpes simplex thymidine kinase gene-transfer in human medulloblastomaGene Therapy, 1998
- HSV-1 thymidine kinase gene therapy for colorectal adenocarcinoma-derived peritoneal carcinomatosisGene Therapy, 1997
- The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctionsGene Therapy, 1997
- The TMC Worldwide Gene Therapy Enrollment Report, End 1996. Report of TMC Development, Paris, FranceHuman Gene Therapy, 1997
- Mechanism of ‘bystander effect’ killing in the herpes simplex thymidine kinase gene therapy model of cancer treatmentGene Therapy, 1997
- Protein and messenger RNA expression of connexin43 in astrocytomas: implications in brain tumor gene therapyJournal of Neurosurgery, 1996
- Gene Therapy for Metastatic Malignant Melanoma: Evaluation of Tolerance to Intratumoral Injection of Cells Producing Recombinant Retroviruses Carrying the Herpes Simplex Virus Type 1 Thymidine Kinase Gene, to be Followed by Ganciclovir Administration. Laboratoire Immunologie B, Hôpital Pitié-Salpêtrière, Paris Cedex, FranceHuman Gene Therapy, 1996
- In VitroEvidence That Metabolic Cooperation Is Responsible for the Bystander Effect Observed with HSVtkRetroviral Gene TherapyHuman Gene Therapy, 1993
- Comparison of Thymidine Kinase Activities Induced in Cells Productively Infected with Herpesvirus Saimiri and Herpes Simplex VirusJournal of General Virology, 1982